Goldman Sachs tips ResMed share price to race higher

The ResMed Inc. (ASX:RMD) share price could race higher after Goldman Sachs lifted its price target…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc. (ASX: RMD) share price was one of the best performers on the ASX 200 last week.

During the period the sleep treatment-focused medical device company's shares recorded a 7% weekly gain.

Why did ResMed's shares race higher?

The driver of this impressive gain was the release of a very strong quarterly update.

That update saw ResMed post first quarter revenue of US$681.1 million, up 16.1% on the prior corresponding period.

Pleasingly, thanks to further improvements in its margins, net operating profit increased at an even quicker rate of 19%. This led to the company posting diluted earnings per share of 93 U.S. cents.

Both its revenue and earnings smashed the market's expectations, leading to investors scrambling to pick up shares.

Is it too late to invest?

I don't believe it is too late to invest. I still see a lot of value in its shares for investors focused on making a buy and hold investment.

This view is echoed by analysts at Goldman Sachs. A note out of the investment bank reveals that they have retained their buy rating and lifted the price target on its shares to $23.20. This price target implies potential upside of more than 10% over the next 12 months.

Goldman was impressed with ResMed's performance in the first quarter, particularly from its masks business. It said: "The greater share of today's +8% beat is driven by masks (+19% in each of US and RoW is the strongest performance since disclosed separately), and 1Q20 is the 9th consecutive quarter of double-digit EBIT growth (+22%)."

And while the broker expects this growth to moderate, it still sees solid growth ahead.

"Whilst these rates are unlikely sustainable, we expect masks to continue to deliver low-teens growth (GSe: +13%), driven by effective portfolio management and successful re-supply programs," it added.

The broker also spoke positively about its valuation. Pointing out that although its shares have hit an all-time high, they are still trading below the healthcare peer group of Cochlear Limited (ASX: COH), CSL Limited (ASX: CSL), and Fisher & Paykel Healthcare Corp Ltd (ASX: FPH).

Overall, I think Goldman makes some great points and suspect its shares may be heading higher again today.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A cute little kid in a suit pulls a shocked face as he talks on his smartphone.
Share Market News

Telstra share price hits 8-year high amid a lacklustre trading week

The ASX 200 communications services sector was the best performer last week, rising 2.96%.

Read more »

share buyers, investors, happy investors
ETFs

How I would build a $100,000 portfolio with ASX ETFs today

You don't need more than three ETFs to build a diversified portfolio...

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »